The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
UBS reconfirmed its 'Buy' rating for Welltower (WELL), a leading healthcare REIT, reflecting continued confidence from analyst Michael Goldsmith. The investment bank also increased its price target for the stock from $228 to $240. This new target suggests a potential upside of 5.26% from current levels. This positive outlook contrasts with Wall Street's average price target of $219.11 for WELL. However, GuruFocus presents a more cautious view, estimating a potential downside based on its GF Value of $145.60. Despite the differing valuations, UBS's move signals a positive sentiment towards Welltower's future performance.
Sign in to access this content
Sign In